Uppsala Monitoring Centre

From WikiMD's Medical Encyclopedia

Revision as of 22:01, 16 February 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Uppsala Monitoring Centre

Logo of the Uppsala Monitoring Centre

The Uppsala Monitoring Centre (UMC) is an independent, non-profit foundation and a centre for international service and scientific research in the field of pharmacovigilance. It is located in Uppsala, Sweden. UMC was established in 1978 to support the World Health Organization's (WHO) Programme for International Drug Monitoring.

History

The Uppsala Monitoring Centre was founded in 1978 as a result of a WHO initiative to create a global system for monitoring the safety of medicines. The centre was established in Uppsala, Sweden, due to the country's strong tradition in pharmaceutical research and development. Since its inception, UMC has played a crucial role in collecting and analyzing data on adverse drug reactions (ADRs) from around the world.

Functions

UMC's primary function is to manage the WHO Programme for International Drug Monitoring, which involves collecting and analyzing reports of adverse drug reactions from member countries. The centre maintains the VigiBase, the largest global database of ADRs, which is used to identify potential safety issues with medicines. UMC also develops tools and methodologies for signal detection and risk assessment in pharmacovigilance.

Research and Development

UMC is involved in various research projects aimed at improving the safety of medicines. The centre collaborates with academic institutions, regulatory authorities, and the pharmaceutical industry to advance the science of pharmacovigilance. UMC also provides training and education to healthcare professionals and regulatory staff worldwide.

Global Impact

The work of UMC has had a significant impact on global public health by improving the safety of medicines. The centre's efforts have led to the identification of numerous safety signals, resulting in changes to drug labels, withdrawal of unsafe medicines, and the development of safer therapeutic alternatives.

Related Pages

References

  • Facade logo of Uppsala Monitoring Centre
    Facade logo of Uppsala Monitoring Centre
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Uppsala_Monitoring_Centre&oldid=6302105"